All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 26, 2021
Home » Blogs » BioWorld MedTech Perspectives » Cures, budgets and cures for the budget blues

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Cures, budgets and cures for the budget blues

July 16, 2015
By Mark McCarty
No Comments

Anything is possible with enough coin, but...
FDA to Congress; Got coin?

Everybody thinks they're poor, but Uncle Sam does have an ongoing deficit problem, and these budget issues are showing up in interesting ways of late.

Needless to say, these problems are affecting the appropriations process, but there may be an escape hatch, and a couple of items of interest for device makers may be at risk, depending on the outcome.

Will user fees cure the Cures problem?

It's time for the negotiations for the next round of device user fees, and the first meeting toward this end was a pretty chummy affair, given how the MDUFA III negotiations ran. The thing I found interesting about industry's comments at the July 13 meeting is how much effort everyone put into saying that user fees are not designed to supplant appropriated jingle, but should be used strictly to augment taxpayer dollars.

Then, acting FDA commish Steve Ostroff made a point of saying that the user fee negotiations and the 21st Century Cures mass movement should be seen as separate but parallel items. Maybe I just have an overactive imagination, but do they all protest too much?

Mark Leahey of the Medical Device Manufacturers Association pointed out that the total user fee schedule has roughly doubled each time the agreement is renewed. Let's remind ourselves that the House Cures bill gives FDA several hundred million dollars less than it needs to handle its end of the Cures program. But going from $595 million over five years under MDUFA III to nearly a billion bucks under MDUFA IV seems like a stretch.

Still, one has to figure user fees are going to rise substantially, and the Cures deal is precisely the sort of thing that will prompt industry to cough up more, especially when one considers how mangled the appropriations process is these days. Speaking of which ...

Another CR to the rescue

The House and Senate are working on spending bills for FDA and agriculture and so on, but President Obama and several Democrats keep arguing the sequester has to go. The President even raised this issue in connection with the 21st Century Cures program, but it's tough to see the political advantage in a veto of this kind of populist, bipartisan bill.

Appropriations bills are a different discussion, though. Democrats and the White House are determined to do away with the sequester, which has no doubt helped constrain budget growth. The problem on the other side is that FDA would lose money if the budget-cutters have their way, and the sources of those user fees know all too well how fungible money can be.

The continuing reliance on continuing resolutions (CRs) has some drawbacks, but one supposes there are worse outcomes. The House budget bill would trim about $2 million from the CDRH budget for 2016, but a CR might leave those numbers more or less even, so that's one advantage. Some in industry do not seem overly concerned about the potential for a CR to drain away a substantial volume of device user fees, a second reason to see a CR as a not-so-poison pill that may be the best available treatment for what's ailing Washington.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing